SCHEMBL5453191

SCHEMBL5453191

NC(=O)c1c(NC(=O)C2CC2)sc2c1CCOC2Nc1ccc(F)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.45
NR1I2 O75469 1/20 0.45
AHR P35869 1/20 0.45
ALDH1A1 P00352 7/20 0.42
MEN1 O00255 2/20 0.42
GAA P10253 2/20 0.42
FLT3 P36888 1/20 0.42
MALT1 Q9UDY8 7/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 2/20 0.37
HPGD P15428 3/20 0.37
TSHR P16473 1/20 0.37
MAPK10 P53779 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MDM2 Q00987 1/20 0.37
TNIK Q9UKE5 1/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 2/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460990 0.78 BTK (0.41) KMT2AALDH1A1MEN1FLT3KDM4E
SCHEMBL5458319 0.76 FLT3 (0.46) KMT2AALDH1A1MEN1GAAFLT3
SCHEMBL5451643 0.73 FLT3 (0.55) KMT2AALDH1A1MEN1FLT3SMN1; SMN2
SCHEMBL5457919 0.73 FLT3 (0.48) KMT2ANR1I2AHRALDH1A1MEN1
SCHEMBL5455200 0.71 FLT3 (0.46) KMT2AALDH1A1MEN1FLT3SMN1; SMN2
SCHEMBL5451709 0.71 FLT3 (0.41) KMT2AALDH1A1MEN1GAAFLT3
SCHEMBL5458311 0.70 FLT3 (0.52) KMT2AALDH1A1MEN1FLT3SMN1; SMN2
SCHEMBL5453060 0.70 CFTR (0.54) KMT2AALDH1A1MEN1HTTKDM4E
SCHEMBL5457860 0.70 FLT3 (0.44) KMT2AALDH1A1MEN1FLT3SMN1; SMN2
SCHEMBL5459168 0.70 FLT3 (0.40) KMT2AALDH1A1FLT3SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 KMT2A 4785/4885NR1I2 3648/4885AHR 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.